Loading...

Online CE Programs

Acromegaly: Improving Timely Diagnosis, Assessment, and Treatment

Acromegaly is a rare, chronic, progressive disease characterized by an excess secretion of growth hormone (GH) and increased circulating insulin-like growth factor 1 (IGF-1) concentrations. It is caused by a pituitary adenoma in most cases. The clinical diagnosis, based on symptoms related to GH excess, is often delayed due to the insidious nature of the disease. Consequently, patients often have established systemic complications at diagnosis with increased morbidity and premature mortality.

Biosimilars in Osteoporosis: Highlights from the ASBMR

Biosimilars are large, complex molecules made from living organisms that are highly similar to their reference biologic and are administered in the same way, with the same strength and dosage, and clinically meaningful differences in safety, purity, and potency.

Incorporating biosimilars into the management of osteoporosis, known as a silent chronic disease responsible for 13 million fragility fractures worldwide, provide a more affordable version of osteoporosis medication, and an alternative to conventional osteoporosis agents.

During this activity, presented as a satellite symposium at the recent ASBMR Annual Meeting, experts will discuss the efficacy and safety of biosimilars, and how these agents are changing the treatment landscape in osteoporosis management.

Metabolic Disorders: Strategies to Improve Management of Porphyrias + Porphyria-like Attacks

Patients with acute porphyrias, characterized by an enzymatic defect in the heme biosynthetic pathway, often present with debilitating, life-threatening attacks. Patients with some inherited metabolic disorders often present with porphyria-like attacks.  

We will be providing an on-demand webinar with highlights from our satellite symposium held at the ACMG annual meeting on March 13th, 2024.  Launch date for webinar is expected around March 25th.  Please check back at that time or click below on "participate" so we can send you a link when launching details are available. Thank you.